GLTO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GLTO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Galecto's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was $-6.56 Mil. It means Galecto's Accounts Payable & Accrued Expense declined by $6.56 Mil from Sep. 2023 to Dec. 2023 .
Galecto's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $-4.98 Mil. It means Galecto's Accounts Payable & Accrued Expense declined by $4.98 Mil from Dec. 2022 to Dec. 2023 .
The historical data trend for Galecto's Change In Payables And Accrued Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galecto Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Change In Payables And Accrued Expense | Get a 7-Day Free Trial | 3.54 | -2.62 | -1.05 | 6.49 | -4.98 |
Galecto Quarterly Data | ||||||||||||||||||||
Dec18 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Change In Payables And Accrued Expense | Get a 7-Day Free Trial | 2.19 | 2.98 | 0.87 | -2.27 | -6.56 |
Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.
Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.98 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Galecto's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.
Orbimed Advisors Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Bertil Lindmark | officer: Chief Medical Officer | C/O GALECTO, INC., OLE MAALOES VEJ 3, COPENHAGEN N G7 DK-2200 |
Hans T. Schambye | director, officer: Chief Executive Officer | C/O GALECTO, INC., OLE MAALOES VEJ 3, COPENHAGEN N G7 DK-2200 |
Stephanie Oestreich | officer: Chief Business Officer | 75 STATE STREET, SUITE 100, BOSTON MA 02109 |
Jonathan Freve | officer: Chief Financial Officer | C/O SPRING BANK PHARMACEUTICALS, INC., 113 CEDAR STREET, STE S-7, MILFORD MA 01757 |
Garrett Winslow | officer: General Counsel | 35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748 |
Anne Prener | director | C/O RUBIUS THERAPEUTICS, 399 BINNEY STREET SUITE 300, CAMBRIDGE MA 02139 |
Dallas Jayson Donald Alexander | director | AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005 |
Novo Holdings A/s | 10 percent owner | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Chau Quang Khuong | director, 10 percent owner | C/O ORBIMED ADVISORS, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Stephan Christgau | director | C/O CASTLE & MORGAN HOLDINGS, INC., 425 MARKET STREET, SUITE 2230, SAN FRANCISCO CA 94105 |
Soren Moller | director | C/O NOVO HOLDINGS A/S, TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Anders Pedersen | officer: Chief Operating Officer | C/O GALECTO, INC., OLE MAALOES VEJ 3, COPENHAGEN N G7 DK-2200 |
Orbimed Advisors Israel Ii Ltd | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Orbimed Israel Gp Ii, L.p. | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
From GuruFocus
By Value_Insider Value_Insider • 10-31-2022
By Value_Insider Value_Insider • 10-17-2022
By GuruFocusNews GuruFocusNews • 07-06-2022
By sperokesalga sperokesalga • 04-13-2023
By Marketwired • 07-31-2023
By Value_Insider Value_Insider • 11-03-2022
By GuruFocusNews GuruFocusNews • 06-30-2022
By Value_Insider Value_Insider • 10-19-2022
By GuruFocusNews GuruFocusNews • 06-26-2022
By Value_Insider Value_Insider • 11-08-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.